Congressman Pete Olson

Representing the 22nd District of Texas

Olson Advocates for a #Path2Cures

June 10, 2015
Press Release

Rep. Pete Olson (TX-22) today announced his strong support for legislation to help deliver more cures, treatments, and therapies to patients and bring our health care system into the 21st century. As a member of the Energy and Commerce Committee, Olson has worked to help gather information from medical innovators on how Congress can help researchers, caregivers, and innovators unleash the power of 21st century science and technology. H.R. 6, the 21st Century Cures Act is the product of more than a year of determining how Congress can help spur medical innovation. The bill passed out of committee by a vote of 51-0 last month and a full House vote is expected soon.

"By providing the necessary support to create medical breakthroughs, we give hope to patients that new and better treatments are on the horizon," Rep. Pete Olson said. "We can close the gap between scientific breakthroughs and regulatory policies. With 21st Century Cures, we are better-equipped to find cures for diseases such as cancer, heart disease, and Alzheimer's. I'm proud of our bipartisan effort to provide a needed blueprint for medical innovation."

“The 21st Century Cures Act will help patients and their loved ones in every community across the country,” said Energy and Commerce Committee Chairman Fred Upton (R-MI). “This has been a nonpartisan and hopeful effort that has thrived from an outpouring of support and feedback from those who know best: patients. Our quest for 21st Century Cures continues and we appreciate all those who have joined us in this effort – there is none that is more important. With every cosponsor, the tide is rising for hope.

Click here to read a joint op/ed by Reps. Pete Olson (R-TX) and Gene Green (D-TX) on the Cures Act. Read a two-page summary of H.R. 6 online HERE.

The 21st Century Cures Act:

  • Removes barriers to increased research collaboration;
  • Incorporates the patient perspective into drug development and regulatory review process;
  • Modernizes clinical trials;
  • Provides new incentives for the development of drugs for rare diseases;
  • Invests in 21st century science and next generation investigation ($2 billion per year for five years at the National Institutes of Health);
  • Helps keep and create jobs here at home.  




Media Contact: Melissa Kelly